What retatrutide effects appeared in Phase 2, the middle tests

What weight loss does not settle about retatrutide safety

Eli Lilly tested retatrutide to lower weight and improve sugar control together. Both improved in studies, but no country had approved the medicine as of 2026.

Stomach trouble grew worse with larger amounts, and some people stopped treatment. Your ability to eat, drink, and stay strong matters alongside a falling weight.

The first kind of evidence here (1) comes from Phase 2, middle tests, and Phase 3, larger tests. Doctors measured changes and checked unwanted effects among the volunteers during treatment.

The second kind (2) comes from people describing retatrutide use they call research. Nobody confirmed their study membership, their shot amounts, or the medical care behind their accounts.

Officials judge a medicine by study findings rather than unchecked personal accounts. An outside bottle doesn't establish genuine retatrutide, the stated amount, or freedom from germs.

What weight, waist, and liver checks found during trials

The 48-week Phase 2 study, a middle test, followed 338 adults with obesity ^[1]. Weekly 12 milligram shots produced average loss of 24.2%, compared with 2.1% on placebo, which contained no retatrutide.

Waists shrank nearly 20 centimeters at the largest amount, roughly the width of a sheet of writing paper. These are changes from starting measurements, rather than extra changes beyond those seen with placebo.

Another Phase 2 trial followed 281 adults with type 2 diabetes ^[2]. The 12 milligram group had better sugar control by 24 weeks and average weight loss of 16.94% by 36 weeks.

Phase 2a, a smaller liver test within that middle stage, followed 98 people with at least 10% liver fat. With 12 milligrams, the amount of fat inside the liver fell 82.4% by 24 weeks ^[5].

In that study, 86% of people reached normal liver-fat levels. Later, at 48 weeks, scans found still less liver fat; that's a change in fat, separate from the count of people.

The first Phase 3 study, a larger test before possible approval, followed 537 adults with type 2 diabetes for 40 weeks. With 12 milligrams, sugar control improved and average weight loss reached 15.3% ^[12].

Unwanted effects led 8.3% of the retatrutide group to stop that treatment. TRIUMPH's further Phase 3 trials still need to answer questions about safety over years that matter to you.

What people say happened during retatrutide research use

People describing research use of retatrutide supplied these accounts; trials with comparison groups have neither checked nor proved their claims. The amount in their shots wasn't confirmed, so you can't judge these accounts as closely watched trial results.

Changes people often liked:

Less interest in food: Some say they no longer think about food all day or feel drawn to meals. Their accounts describe fewer urges to eat, rather than just a full stomach after a meal.

Early drops on the scale: Some noticed weight falling during the first weeks, sometimes faster than with related medicines. Phase 2/3, middle and larger tests, also found big losses, though study care differs from unchecked research use.

Changes people had mixed feelings about:

Extra sweating and a warmer feeling: Some say everyday tasks leave them flushed, warm, or sweating more than before. Their suggested cause is glucagon, a hormone involved in using calories, though the reports don't prove the cause.

Feeling less troubled by food: Some feel less worried about meals and happier while losing weight. They link this to GLP-1, a hunger hormone, though a controlled study hasn't tested that explanation for these accounts.

The most reported problem:

Feeling sick to the stomach: People often said nausea was worst 4–8 hours after a shot or after an increase. Many said nausea eased later; Phase 2 trials also found sick stomachs in up to 45% at the largest amount.

Other unwanted changes people described often:

A quicker pulse at rest: Some saw their watches show rises of 5–15 beats per minute after injections. Phase 2 trials measured faster pulses too ^[1], but your watch cannot tell you whether a pulse change is safe.

Burps that smell of rotten eggs: Some report bad-smelling burps that appear now and then and sometimes ease later. They suspect GLP-1 slows food leaving the stomach, but the cause remains unproved in their accounts.

Tiredness in the early weeks: Some describe heavy legs, needing more sleep, or feeling foggy and worn out after shots. They suspect a sharp fall in food intake, though no trial tested that explanation for these particular accounts.

Constipation, or trouble passing stool: Some say they go to the toilet less often while eating far less. The drug slowing food passing along the gut might contribute, but the accounts cannot tell which cause matters most.

Unwanted changes people described less often:

Itching or redness after the needle: Some say mild skin trouble settled within 24–48 hours. About 8% had a skin reaction to injections in Phase 2 ^[1], so doctors found this problem too.

Trouble sleeping at first: Some found falling asleep or staying asleep harder during the first weeks of use. The reason is unknown, including whether retatrutide caused the change in sleep.

Worries about losing muscle with fat: Some feared weaker muscles as their weight dropped, especially when the loss felt rapid. Phase 2 tests found lost weight included muscle and other body parts besides fat; those tests didn't measure muscle alone.

How retatrutide side effects interrupted treatment

Phase 2, middle tests before larger trials, found gut trouble and faster pulses during treatment. These problems sometimes led people to stop the shots, so weight loss alone can't tell you how treatment felt.

What stomach trouble, faster pulses, and muscle loss can mean

An unchecked bottle may hold something else: Retatrutide remained unapproved worldwide in mid-2026. Outside bottles lack the checks required for an approved medicine.

Tests of related drugs sold for research found some had broken down or held contents different from their labels. These results don't confirm what any particular retatrutide bottle contains.

Germs and harmful substances left by bacteria can enter materials used for shots. Severe infection can follow, including sepsis, a dangerous response to infection; FDA warning letters challenged retatrutide sales in 2025.

Stomach problems worsened as amounts rose: In the 48-week Phase 2 obesity test, up to 45% at the largest amount felt nauseated. Nausea, that sick feeling in the stomach, drove much of the 18% stopping rate at that amount ^[1].

The GLP-1 hormone action slows the passage of food out of your stomach. Without a doctor checking increases, severe gut trouble may leave you short of fluid and salts your body needs.

A faster pulse leaves heart questions unanswered: Phase 2 measured average rises of about 5–7 beats per minute with the largest amounts. The rises peaked near week 24 ^[1]; glucagon's action can make the heart beat faster.

A separate heart study continued, with no results yet available to explain lasting safety. Irregular beats and lasting changes in the heart remained unanswered questions for you.

Insulin and some other diabetes medicines can lower sugar too far: Retatrutide copies GLP-1 and GIP, hormones that prompt the body to release insulin. With insulin or medicines that prompt extra insulin release, retatrutide may lower sugar dangerously.

In Phase 2, people already receiving insulin needed their insulin amount lowered ^[2]. Without medical checks, the combined medicines could lower your sugar too far before the problem is caught.

Lost weight included more than fat: A 2025 study in The Lancet Diabetes and Endocrinology examined people with type 2 diabetes. Fat fell, but so did weight from muscle, body water, and organs; the test didn't separate muscle loss.

The share lost as fat was better than in older reports of weight-loss surgery. Even so, losing muscle matters to your strength, particularly in later life or when your muscles are already weak.

Safety over years and weight after stopping remain unknown: TRIUMPH continued alongside further trials examining the heart and kidneys as of mid-2026. Phase 2 findings with similar hunger medicines showed weight returning after treatment ended ^[13][14], but retatrutide's own answer remained unknown.